EXTENDING INDEPENDENCE AND QUALITY OF LIFE FOR PEOPLE WITH ALZHEIMER'S DISEASE OR DEMENTIA THROUGH TELEHEALTH PROGRAM DELIVERY
通过远程医疗计划的实施,提高阿尔茨海默病或痴呆症患者的独立性和生活质量
基本信息
- 批准号:10019891
- 负责人:
- 金额:$ 142.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAlzheimer&aposs disease caregiverAmericanBehavior TherapyBehavioralCaliforniaCaregiversCaringChildClientClinical TrialsCognitiveCommunitiesControl GroupsCouplesDementiaDevelopmentDevicesDiseaseDoseEducationElementsEmotionalEnvironmentEvidence based programFeedbackFriendsGeriatricsGoalsGrantGrowthHealthHome environmentHumanIntegrative MedicineIntervention StudiesLogisticsMeasuresMemory LossMethodsMissionModelingParentsParticipantPersonal SatisfactionPersonsPharmaceutical PreparationsPhasePreparationPrevalencePsychologyPublic HealthQualitative MethodsQuality of lifeRandomized Controlled TrialsReportingResearch PersonnelResearch ProposalsSan FranciscoSmall Business Innovation Research GrantSocial ProblemsSocial isolationStreamSymptomsTeacher Professional DevelopmentTechnologyTestingThinkingTraining ProgramsTraining SupportTransportationTriad Acrylic ResinUnderserved PopulationUniversitiesVulnerable PopulationsWaiting Listsbasecohortcommercializationdesigndigitaldistractionevidence baseexperienceimprovedinnovationinnovative technologiesinstructormild cognitive impairmentnovel strategiesprogramsprototyperesponseside effectsocialtelehealthtooluser-friendlyvirtualweb portalweb site
项目摘要
Mission Statement: Together Senior Health, Inc. (TOGETHER), is committed to helping people living with
Alzheimer’s Disease and Related Disorders (ADRD) and their caregivers maximize quality of life by delivering
livestreaming, evidence-based, virtual group programs to them in their homes. Significance: There are
currently 5.8 million people in the U.S. living with ADRD and more than 16 million unpaid caregivers. Current
ADRD medications help with some symptoms but do not change the disease course and are often stopped
due to side effects. In addition, most evidence-based behavioral interventions—such as our in-person Moving
Together program—are not widely available to people in their local communities. Innovation: TOGETHER is
bridging this gap by using human centered design principles—in which the user is involved with all phases of
design and testing—to develop and test an innovative, user-friendly platform for delivering livestreaming virtual
group programs to people with ADRD and caregivers in their homes. Investigators: TOGETHER’s CEO and
PI of this application has expertise in human centered design and successfully led our Phase I Small Business
Innovation Research (SBIR) grant. Coinvestigators and consultants bring expertise in clinical trials, integrative
health, behavioral psychology, geriatrics, qualitative methods, technology and education. Approach: Phase I
Progress. Our Phase I SBIR enabled us to develop and demonstrate proof-of-concept for our unique approach
to livestreaming virtual group program delivery. We have completed or exceeded all of our milestones, which
included: 1) creating the platform in partnership with graduates of our in-person program; 2) pilot-testing the
platform in a naïve group of users and 3) refining the platform in preparation for Phase II. The response has
been exceptional, with participants highlighting many physical, social, emotional, and logistical benefits. Phase
II Aims: The primary goals of this SBIR Phase II grant are to: 1) determine whether livestreaming virtual group
delivery of the Moving Together program improves quality of life in people with mild ADRD and caregivers,
including exploration of potential mechanisms of action; 2) refine the platform for people with mild cognitive
impairment to expand our target audience; and 3) develop an instructor training program to meet the needs of
a larger client base. Environment: TOGETHER’S corporate office is in San Francisco, which offers a rich
environment for developing and testing innovative technology-based solutions to challenging social problems
and is enhanced by involvement of investigators at the University of California, San Francisco (UCSF) and San
Francisco VA. Commercialization Plan: After completion of Phase II, we will be prepared to commercialize
TOGETHER’s telehealth platform, initially using a client pay model, with clear plans for growth and expansion.
Summary: TOGETHER’s innovative approach to livestreaming virtual group delivery of evidence-based
programs for people with ADRD and caregivers in their homes offers tremendous potential to increase access
and improve quality of life in this vulnerable and under-served population.
使命宣言:Together Senior Health, Inc. (TOGETHER) 致力于帮助患有以下疾病的人们
阿尔茨海默氏病及相关疾病 (ADRD) 及其护理人员通过提供
在家中向他们提供基于证据的直播、虚拟团体节目 意义:有。
目前,美国有 580 万人患有 ADRD,并且有超过 1600 万无薪护理人员。
ADRD 药物有助于缓解某些症状,但不会改变病程,并且通常会停止使用
此外,大多数基于证据的行为干预措施,例如我们的亲自搬家。
Together 计划——当地社区的人们并未广泛参与创新:TOGETHER 是。
通过使用以人为本的设计原则来弥合这一差距,其中用户参与了所有阶段
设计和测试——开发和测试一个创新的、用户友好的平台,用于提供虚拟直播
针对 ADRD 患者和家中护理人员的团体计划:TOGETHER 的首席执行官和
该应用程序的 PI 拥有以人为本的设计方面的专业知识,并成功领导了我们的第一阶段小型企业
创新研究 (SBIR) 资助,共同研究者和顾问带来临床试验、综合方面的专业知识。
健康、行为心理学、老年病学、定性方法、技术和教育。
第一阶段 SBIR 的进展使我们能够开发并演示我们独特方法的概念验证。
我们已经完成或超越了所有里程碑。
包括:1) 与我们的面对面项目的毕业生合作创建平台;2) 进行试点测试
3) 完善平台,为第二阶段做准备。
非常出色,突出了许多身体、社交、情感和后勤方面的好处。
II 目标:SBIR 第二阶段资助的主要目标是:1)确定直播虚拟群组是否
“一起行动”计划的实施可改善轻度 ADRD 患者和护理人员的生活质量,
2)完善针对轻度认知人群的平台
扩大我们的目标受众;以及 3) 制定教练培训计划以满足以下人员的需求:
更大的客户群:TOGETHER 的公司办公室位于旧金山,提供丰富的服务。
开发和测试基于创新技术的解决方案以应对具有挑战性的社会问题的环境
加州大学旧金山分校 (UCSF) 和旧金山大学的研究人员的参与得到了加强
Francisco VA。商业化计划:第二阶段完成后,我们将准备商业化。
TOGETHER 的远程医疗平台最初采用客户付费模式,并制定了明确的增长和扩张计划。
摘要:TOGETHER 的创新方法通过直播虚拟小组交付基于证据的内容
针对 ADRD 患者及其家中护理人员的计划为增加获得服务的机会提供了巨大潜力
并改善这些弱势且服务不足的人群的生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Deborah E. Barnes其他文献
Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research.
行业资助的研究和利益冲突:对烟草行业通过室内空气研究中心赞助的研究进行分析。
- DOI:
10.1215/03616878-21-3-515 - 发表时间:
1996-06-01 - 期刊:
- 影响因子:0
- 作者:
Deborah E. Barnes;L. Bero - 通讯作者:
L. Bero
Transcription coupled repair of 8-oxoguanine in murine cells: the ogg1 protein is required for repair in nontranscribed sequences but not in transcribed sequences.
鼠细胞中 8-氧代鸟嘌呤的转录偶联修复:非转录序列的修复需要 ogg1 蛋白,但转录序列则不需要。
- DOI:
10.1073/pnas.140137297 - 发表时间:
2000-07-18 - 期刊:
- 影响因子:11.1
- 作者:
F. L. Page;Arne Klungl;Deborah E. Barnes;Alain Sarasin;Serge Boiteux - 通讯作者:
Serge Boiteux
Why review articles on the health effects of passive smoking reach different conclusions.
为什么有关被动吸烟对健康影响的评论文章得出不同的结论。
- DOI:
10.1001/jama.279.19.1566 - 发表时间:
1998-05-20 - 期刊:
- 影响因子:0
- 作者:
Deborah E. Barnes;L. Bero - 通讯作者:
L. Bero
Scientific quality of original research articles on environmental tobacco smoke
关于环境烟草烟雾的原创研究文章的科学质量
- DOI:
10.1136/tc.6.1.19 - 发表时间:
1997-03-01 - 期刊:
- 影响因子:5.2
- 作者:
Deborah E. Barnes;L. Bero - 通讯作者:
L. Bero
Prediction of Recovery, Dependence or Death in Elders Who Become Disabled During Hospitalization
住院期间残疾老年人的康复、依赖或死亡预测
- DOI:
10.1007/s11606-012-2226-y - 发表时间:
2013-02-01 - 期刊:
- 影响因子:5.7
- 作者:
Deborah E. Barnes;Kala M. Mehta;W. J. Boscardin;R. Fortinsky;Robert M. Palmer;Katharine A. Kirby;C. Landefeld - 通讯作者:
C. Landefeld
Deborah E. Barnes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Deborah E. Barnes', 18)}}的其他基金
A Novel Algorithm to Identify People with Undiagnosed Alzheimer's Disease and Related Dementias
一种识别未确诊阿尔茨海默病和相关痴呆症患者的新算法
- 批准号:
10696912 - 财政年份:2023
- 资助金额:
$ 142.87万 - 项目类别:
A Novel Algorithm to Identify People with Undiagnosed Alzheimer's Disease and Related Dementias
一种识别未确诊阿尔茨海默病和相关痴呆症患者的新算法
- 批准号:
10696912 - 财政年份:2023
- 资助金额:
$ 142.87万 - 项目类别:
BRAIN HEALTH TOGETHER: A LIVE-STREAMING GROUP-BASED DIGITAL PROGRAM
共同促进大脑健康:基于小组的直播数字节目
- 批准号:
10324919 - 财政年份:2021
- 资助金额:
$ 142.87万 - 项目类别:
BRAIN HEALTH TOGETHER: A LIVE-STREAMING GROUP-BASED DIGITAL PROGRAM
共同促进大脑健康:基于小组的直播数字节目
- 批准号:
10493302 - 财政年份:2021
- 资助金额:
$ 142.87万 - 项目类别:
BRAIN HEALTH TOGETHER: A LIVE-STREAMING GROUP-BASED DIGITAL PROGRAM
共同促进大脑健康:基于小组的直播数字节目
- 批准号:
10747235 - 财政年份:2021
- 资助金额:
$ 142.87万 - 项目类别:
EXTENDING INDEPENDENCE AND QUALITY OF LIFE FOR PEOPLE WITH ALZHEIMER'S DISEASE OR DEMENTIA THROUGH TELEHEALTH PROGRAM DELIVERY
通过远程医疗计划的实施,提高阿尔茨海默病或痴呆症患者的独立性和生活质量
- 批准号:
10204865 - 财政年份:2020
- 资助金额:
$ 142.87万 - 项目类别:
Low-cost detection of dementia using electronic health records data: validation and testing of the eRADAR algorithm in a pragmatic, patient-centered trial.
使用电子健康记录数据低成本检测痴呆症:在务实、以患者为中心的试验中验证和测试 eRADAR 算法。
- 批准号:
10443874 - 财政年份:2020
- 资助金额:
$ 142.87万 - 项目类别:
Identifying and supporting patients with undiagnosed dementia using the EHR Risk of Alzheimer's and Dementia Assessment Rule (eRADAR): a pilot clinical trial
使用 EHR 阿尔茨海默氏症和痴呆症风险评估规则 (eRADAR) 识别和支持未确诊的痴呆症患者:一项试点临床试验
- 批准号:
10665566 - 财政年份:2020
- 资助金额:
$ 142.87万 - 项目类别:
Low-cost detection of dementia using electronic health records data: validation and testing of the eRADAR algorithm in a pragmatic, patient-centered trial.
使用电子健康记录数据低成本检测痴呆症:在务实、以患者为中心的试验中验证和测试 eRADAR 算法。
- 批准号:
10091300 - 财政年份:2020
- 资助金额:
$ 142.87万 - 项目类别:
Identifying and supporting patients with undiagnosed dementia using the EHR Risk of Alzheimer's and Dementia Assessment Rule (eRADAR): a pilot clinical trial
使用 EHR 阿尔茨海默氏症和痴呆症风险评估规则 (eRADAR) 识别和支持未确诊的痴呆症患者:一项试点临床试验
- 批准号:
10409614 - 财政年份:2020
- 资助金额:
$ 142.87万 - 项目类别:
相似国自然基金
基于神经退行性疾病前瞻性队列的新烟碱类杀虫剂暴露对阿尔茨海默病的影响及作用机制研究
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
基于miRNA介导ceRNA网络调控作用的防治阿尔茨海默病及认知障碍相关疾病药物的发现研究
- 批准号:
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
LMTK1调控核内体转运介导阿尔茨海默病神经元Reserve机制研究
- 批准号:81903703
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
MBP酶切L1CAM介导的线粒体自噬在阿尔茨海默病中的作用和机制
- 批准号:81901296
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
基于自组装多肽纳米探针检测蛋白标志物用于阿尔茨海默病精准诊断的研究
- 批准号:31900984
- 批准年份:2019
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
- 批准号:
10676358 - 财政年份:2024
- 资助金额:
$ 142.87万 - 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 142.87万 - 项目类别:
The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
- 批准号:
10748606 - 财政年份:2024
- 资助金额:
$ 142.87万 - 项目类别:
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
- 批准号:
10752555 - 财政年份:2024
- 资助金额:
$ 142.87万 - 项目类别: